AIM: Prostate contouring using CT alone is difficult. To overcome the uncertainty, CT/MRI registration using a fiducial marker is generally performed. However, visualization of the marker itself can be difficult with MRI. This study aimed to determine the optimal MRI pulse sequence for defining the marker as well as the prostate outline among five sequences. MATERIALS AND METHODS: A total of 21 consecutive patients with prostate cancer were enrolled. Two gold fiducial markers were placed before CT/MRI examination. We used the following five sequences: T1-weighted spin-echo (T1WI; TR/TE, 400-650/8 ms); T2-weighted fast spin-echo (T2WI; 4000/80); T2*-2D-weighted gradient echo (T2*2D; 700/18); T2*-3D-weighted gradient echo (T2*3D; TR/TE1/deltaTE, 37/14/7.3); and contrast-enhanced T1-weighted spin-echo (CE-T1WI; 400-650/8). Qualitative image analysis of the sequences was performed by three observers. These observers subjectively scored all images on a scale of 1-3 (1 = unclear, 2 = moderate, 3 = well visualized). A higher score indicated better visualization. RESULTS: T2WI was significantly superior to the other sequences in terms of prostate definition. T2*2D and T2*3D were strongly superior to the other sequences and were significantly superior in terms of fiducial marker definition. CONCLUSIONS: T2*2D and T2*3D are superior to the other sequences for prostate contouring and marker identification. Therefore, we recommend initial T2*3D and T2*2D examinations.
AIM: Prostate contouring using CT alone is difficult. To overcome the uncertainty, CT/MRI registration using a fiducial marker is generally performed. However, visualization of the marker itself can be difficult with MRI. This study aimed to determine the optimal MRI pulse sequence for defining the marker as well as the prostate outline among five sequences. MATERIALS AND METHODS: A total of 21 consecutive patients with prostate cancer were enrolled. Two gold fiducial markers were placed before CT/MRI examination. We used the following five sequences: T1-weighted spin-echo (T1WI; TR/TE, 400-650/8 ms); T2-weighted fast spin-echo (T2WI; 4000/80); T2*-2D-weighted gradient echo (T2*2D; 700/18); T2*-3D-weighted gradient echo (T2*3D; TR/TE1/deltaTE, 37/14/7.3); and contrast-enhanced T1-weighted spin-echo (CE-T1WI; 400-650/8). Qualitative image analysis of the sequences was performed by three observers. These observers subjectively scored all images on a scale of 1-3 (1 = unclear, 2 = moderate, 3 = well visualized). A higher score indicated better visualization. RESULTS: T2WI was significantly superior to the other sequences in terms of prostate definition. T2*2D and T2*3D were strongly superior to the other sequences and were significantly superior in terms of fiducial marker definition. CONCLUSIONS: T2*2D and T2*3D are superior to the other sequences for prostate contouring and marker identification. Therefore, we recommend initial T2*3D and T2*2D examinations.
Authors: Henkjan J Huisman; Jurgen J Fütterer; Emile N J T van Lin; Arjan Welmers; Tom W J Scheenen; Jorn A van Dalen; Andries G Visser; J A Witjes; Jelle O Barentsz Journal: Radiology Date: 2005-06-27 Impact factor: 11.105
Authors: Robert C Susil; Cynthia Ménard; Axel Krieger; Jonathan A Coleman; Kevin Camphausen; Peter Choyke; Gabor Fichtinger; Louis L Whitcomb; C Norman Coleman; Ergin Atalar Journal: J Urol Date: 2006-01 Impact factor: 7.450
Authors: Mika Kapanen; Juhani Collan; Annette Beule; Tiina Seppälä; Kauko Saarilahti; Mikko Tenhunen Journal: Magn Reson Med Date: 2012-08-10 Impact factor: 4.668
Authors: Soumya Ghose; Jhimli Mitra; David Rivest-Hénault; Amir Fazlollahi; Peter Stanwell; Peter Pichler; Jidi Sun; Jurgen Fripp; Peter B Greer; Jason A Dowling Journal: Med Phys Date: 2016-05 Impact factor: 4.071
Authors: Alan M Nichol; Kristy K Brock; Gina A Lockwood; Douglas J Moseley; Tara Rosewall; Padraig R Warde; Charles N Catton; David A Jaffray Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: S F Riches; G S Payne; N M Desouza; D Dearnaley; V A Morgan; S C Morgan; M Partridge Journal: Br J Radiol Date: 2014-03-06 Impact factor: 3.039